Corubrutinib vs Tolebrutinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: Bruton's tyrosine kinase (BTK) · full Multiple Sclerosis pipeline
Corubrutinib
Developed by Biogen
NCT05798520 · Phase 2 · completed
The study randomized 127 participants and used quadruple blinding with active and matching-placebo comparator arms. Its primary outcomes included adverse events and new MRI lesions.
Company statement of 2026-07-29 (Q2 results); no efficacy figures published yet.
Reported efficacy
Part 1: Number of Participants With Adverse Events (AEs) (Day 1 up to Week 50); Part 1: Number of Participants With Serious Adverse Events (SAEs) (From signing the informed consent form (ICF) to Week 50); Part 2: Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions (Week 8 to Week 16): Biogen reported that BIIB091 achieved proof-of-concept in relapsing-remitting MS (no figures released)
Result source: NCT05798520
Tolebrutinib
Marketed by Sanofi
NCT04411641 · Phase 3 · completed
The trial randomized 1,131 participants in a 2:1 ratio to double-blind tolebrutinib or matching placebo, with participants, investigators, and outcome assessors masked. Its primary clinical endpoint—6-month confirmed disability progression measured by EDSS—was statistically met, with a hazard ratio of 0.693 (95% CI 0.546–0.880; p=0.0026).
Next expected readout: April 2029 · NCT06372145 (registry estimate)
Reported efficacy
Time to Onset of 6-Month Confirmed Disability Progression (CDP) as Assessed by Expanded Disability Status Scale (EDSS) (Baseline (Day 1) up to approximately 47 months): HERCULES (n=1,131, nrSPMS), primary endpoint time to onset of 6-month confirmed disability progression on EDSS: tolebrutinib 60 mg vs placebo HR 0.693 (95% CI 0.546 to 0.880), Cox regression p=0.0026 (CT.gov posted results). (met)
Result source: NCT04411641
Results for Multiple Sclerosis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Corubrutinib | Tolebrutinib |
|---|---|---|
| Annualised relapse rate | —Not reported | 0.1 vs 0.1vs TeriflunomideNCT044109781 other result
|
| Free of 3-month confirmed disability progression (%) | —Not reported | —Not posted · NCT04458051 |
| New or enlarging T2 lesions | —Not reported | 0.2 vs 2.1−1.9 vs placeboNCT038896393 other results
|
Annualised relapse rate
- Corubrutinib
- —Not reported
- Tolebrutinib
- 0.1 vs 0.1vs TeriflunomideNCT04410978
1 other result
- 0.1 vs 0.1 NCT04410991
Free of 3-month confirmed disability progression (%)
- Corubrutinib
- —Not reported
- Tolebrutinib
- —Not posted · NCT04458051
New or enlarging T2 lesions
- Corubrutinib
- —Not reported
- Tolebrutinib
- 0.2 vs 2.1−1.9 vs placeboNCT03889639
3 other results
- 1.3 vs 2.1 NCT03889639
- 1.3 vs 2.1 NCT03889639
- 1.9 vs 2.1 NCT03889639
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Corubrutinib: 0 of 4 rows · Tolebrutinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Tolebrutinib |
|---|---|
| Dropout rate | 42.4%60 mga NCT04411641 · Phase 3 · monotherapy · Multiple Sclerosis, Secondary Progressive Multiple Sclerosis · phase 3 show 14 more results15.8%60 mg NCT04410978 · Phase 3 · Multiple Sclerosis · phase 3 14.1%60 mg NCT04410991 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 0%60 mg NCT03996291 · Phase 2 · registry result, not featured evidence —15/60 mg NCT03996291 · Phase 2 · registry result, not featured evidence —30/60 mg NCT03996291 · Phase 2 · registry result, not featured evidence —5/60 mg NCT03996291 · Phase 2 · registry result, not featured evidence —60/60 mg NCT03996291 · Phase 2 · registry result, not featured evidence 0%30 mg NCT03996291 · Phase 2 · registry result, not featured evidence 0%15 mg NCT03996291 · Phase 2 · registry result, not featured evidence 3.2%5 mg NCT03996291 · Phase 2 · registry result, not featured evidence —60 mg NCT03889639 · Phase 2 · registry result, not featured evidence —30 mg NCT03889639 · Phase 2 · registry result, not featured evidence —15 mg NCT03889639 · Phase 2 · registry result, not featured evidence —5 mg NCT03889639 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 3.8%60 mga NCT04411641 · Phase 3 · monotherapy · Multiple Sclerosis, Secondary Progressive Multiple Sclerosis · phase 3 show 14 more results—60 mg NCT04410978 · Phase 3 · Multiple Sclerosis · phase 3 —60 mg NCT04410991 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 —60 mg NCT03996291 · Phase 2 · registry result, not featured evidence —15/60 mg NCT03996291 · Phase 2 · registry result, not featured evidence —30/60 mg NCT03996291 · Phase 2 · registry result, not featured evidence —5/60 mg NCT03996291 · Phase 2 · registry result, not featured evidence —60/60 mg NCT03996291 · Phase 2 · registry result, not featured evidence —30 mg NCT03996291 · Phase 2 · registry result, not featured evidence —15 mg NCT03996291 · Phase 2 · registry result, not featured evidence —5 mg NCT03996291 · Phase 2 · registry result, not featured evidence —60 mg NCT03889639 · Phase 2 · registry result, not featured evidence —30 mg NCT03889639 · Phase 2 · registry result, not featured evidence —15 mg NCT03889639 · Phase 2 · registry result, not featured evidence —5 mg NCT03889639 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 15%60 mga NCT04411641 · Phase 3 · monotherapy · Multiple Sclerosis, Secondary Progressive Multiple Sclerosis · phase 3 show 14 more results8.6%60 mg NCT04410978 · Phase 3 · Multiple Sclerosis · phase 3 11%60 mg NCT04410991 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 6.5%60 mg NCT03996291 · Phase 2 · registry result, not featured evidence 9.7%15/60 mg NCT03996291 · Phase 2 · registry result, not featured evidence 9.4%30/60 mg NCT03996291 · Phase 2 · registry result, not featured evidence 16.7%5/60 mg NCT03996291 · Phase 2 · registry result, not featured evidence 9.7%60/60 mg NCT03996291 · Phase 2 · registry result, not featured evidence 3.1%30 mg NCT03996291 · Phase 2 · registry result, not featured evidence 6.5%15 mg NCT03996291 · Phase 2 · registry result, not featured evidence 0%5 mg NCT03996291 · Phase 2 · registry result, not featured evidence 3.1%60 mg NCT03889639 · Phase 2 · registry result, not featured evidence 0%30 mg NCT03889639 · Phase 2 · registry result, not featured evidence 0%15 mg NCT03889639 · Phase 2 · registry result, not featured evidence 0%5 mg NCT03889639 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 60 mga covid-19 24.6% (placebo 22.7%) urinary tract infection 10.9% (placebo 13.1%) fall 9.3% (placebo 10.7%) NCT04411641 · Phase 3 · monotherapy · Multiple Sclerosis, Secondary Progressive Multiple Sclerosis · phase 3 show 14 more results60 mg covid-19 24.1% nasopharyngitis 12.1% headache 11.5% NCT04410978 · Phase 3 · Multiple Sclerosis · phase 3 60 mg covid-19 23.7% headache 13.6% nasopharyngitis 13.4% NCT04410991 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 60 mg viral upper respiratory tract infection 16.1% headache 9.7% back pain 6.5% NCT03996291 · Phase 2 · registry result, not featured evidence 15/60 mg covid-19 32.3% nasopharyngitis 19.4% back pain 16.1% NCT03996291 · Phase 2 · registry result, not featured evidence 30/60 mg covid-19 21.9% urinary tract infection 15.6% hypertension 12.5% NCT03996291 · Phase 2 · registry result, not featured evidence 5/60 mg covid-19 33.3% back pain 20% nasopharyngitis 16.7% NCT03996291 · Phase 2 · registry result, not featured evidence 60/60 mg covid-19 45.2% nasopharyngitis 19.4% arthralgia 16.1% NCT03996291 · Phase 2 · registry result, not featured evidence 30 mg headache 12.5% nasopharyngitis 9.4% pyrexia 6.3% NCT03996291 · Phase 2 · registry result, not featured evidence 15 mg tension headache 6.5% upper respiratory tract infection 6.5% fall 3.2% NCT03996291 · Phase 2 · registry result, not featured evidence 5 mg headache 9.7% dry skin 6.5% pyrexia 6.5% NCT03996291 · Phase 2 · registry result, not featured evidence 60 mg headache 12.5% (placebo 3.1%) accidental overdose 9.4% (placebo 0%) nasopharyngitis 9.4% (placebo 1.6%) NCT03889639 · Phase 2 · registry result, not featured evidence 30 mg back pain 6.1% (placebo 0%) acne 3% (placebo 0%) alanine aminotransferase increased 3% (placebo 0%) NCT03889639 · Phase 2 · registry result, not featured evidence 15 mg headache 9.4% (placebo 3.1%) rhinitis 6.3% (placebo 0%) upper respiratory tract infection 6.3% (placebo 0%) NCT03889639 · Phase 2 · registry result, not featured evidence 5 mg oedema peripheral 6.1% (placebo 3.1%) upper respiratory tract infection 6.1% (placebo 0%) alanine aminotransferase increased 3% (placebo 0%) NCT03889639 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 12 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Tolebrutinib
show 2 more results
show 2 more results
show 1 more result
show 2 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 9 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Corubrutinib's landscape · Tolebrutinib's landscape